Abstract
O-1602 is a cannabidiol analogue that does not bind with high affinity to either the cannabinoid CB1 receptor or CB2 receptor. However, there is evidence that O-1602 has significant effects in the central nervous system as well as other parts of the body. Depending upon the model, O-1602 has anti-inflammatory or pronociceptive effects, mediated through a number of distinct receptors. This article reviews the evidence for functional effects of O-1602, particularly in the CNS, and describes its known targets as they relate to these effects. These include the abnormal cannabidiol (Abn- CBD) receptor and GPR55. The GPR18 receptor has been identified with the Abn-CBD receptor, and therefore the evidence that O-1602 also acts at GPR18 is also reviewed. Finally, the evidence that these receptor targets are expressed in the CNS and the phenotypes of cells expressing these targets is discussed, concluding with a discussion of the prospects for O-1602 as a therapeutic agent in the CNS.
Keywords: Abnormal Cannabidiol, Cannabidiol, Cannabinoid, inflammation, GPR18, GPR55, O-1602, microglia.
Central Nervous System Agents in Medicinal Chemistry
Title:The Atypical Cannabinoid O-1602: Targets, Actions, and the Central Nervous System
Volume: 12 Issue: 3
Author(s): John C. Ashton
Affiliation:
Keywords: Abnormal Cannabidiol, Cannabidiol, Cannabinoid, inflammation, GPR18, GPR55, O-1602, microglia.
Abstract: O-1602 is a cannabidiol analogue that does not bind with high affinity to either the cannabinoid CB1 receptor or CB2 receptor. However, there is evidence that O-1602 has significant effects in the central nervous system as well as other parts of the body. Depending upon the model, O-1602 has anti-inflammatory or pronociceptive effects, mediated through a number of distinct receptors. This article reviews the evidence for functional effects of O-1602, particularly in the CNS, and describes its known targets as they relate to these effects. These include the abnormal cannabidiol (Abn- CBD) receptor and GPR55. The GPR18 receptor has been identified with the Abn-CBD receptor, and therefore the evidence that O-1602 also acts at GPR18 is also reviewed. Finally, the evidence that these receptor targets are expressed in the CNS and the phenotypes of cells expressing these targets is discussed, concluding with a discussion of the prospects for O-1602 as a therapeutic agent in the CNS.
Export Options
About this article
Cite this article as:
C. Ashton John, The Atypical Cannabinoid O-1602: Targets, Actions, and the Central Nervous System, Central Nervous System Agents in Medicinal Chemistry 2012; 12 (3) . https://dx.doi.org/10.2174/187152412802430156
DOI https://dx.doi.org/10.2174/187152412802430156 |
Print ISSN 1871-5249 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6166 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Tailored Angiogenesis Inhibition in Cancer Therapy: Respecting the Heart to Improve the Net Outcome
Current Signal Transduction Therapy The Role of Cytokine Network in the Pathophysiology of Schizophrenia
Current Psychiatry Reviews Hypoxic Preconditioning Increases Blood-Brain Barrier Disruption in the Early Stages of Cerebral Ischemia
Current Neurovascular Research Efficacy and Toxicity of Clioquinol Treatment and A-beta42 Inoculation in the APP/PSI Mouse Model of Alzheimer's Disease
Current Alzheimer Research Pharmacological Strategies for Neuroprotection in Traumatic Brain Injury
Mini-Reviews in Medicinal Chemistry Antidotes for Acute Cyanide Poisoning
Current Pharmaceutical Biotechnology Connecting Parkinsons Disease and Drug Addiction: Common Players Reveal Unexpected Disease Connections and Novel Therapeutic Approaches
Current Pharmaceutical Design Noninvasive Diagnosis of Chemotherapy Related Cardiotoxicity
Current Cardiology Reviews Non-Coding RNA in Brain Development and Disorder
Current Medicinal Chemistry Inflammatory Mechanisms of Injury and Recovery after Intracerebral Hemorrhage
Current Immunology Reviews (Discontinued) Utilizing Delta Opioid Receptors and Peptides for Cytoprotection: Implications in Stroke and Other Neurological Disorders
CNS & Neurological Disorders - Drug Targets Metabolic Fate of Endocannabinoids
Current Neuropharmacology Current Clinical Applications of In Vivo Magnetic Resonance Spectroscopy and Spectroscopic Imaging
Current Medical Imaging NOX3-Targeted Therapies for Inner Ear Pathologies
Current Pharmaceutical Design Growth Factor Changes in Cerebrospinal Fluid of Children with Mental Retardation before and after Neural Precursor Cell Transplantation
CNS & Neurological Disorders - Drug Targets Adenosine in the Inflamed Gut: A Janus Faced Compound
Current Medicinal Chemistry Retraction Notice: The Benefits and Risks of Different Therapies in Preventing Postoperative Nausea and Vomiting in Patients Undergoing Thyroid Surgery
Current Drug Safety Bradykinin Receptors in Ischemic Injury
Current Neurovascular Research Micro- and Macrovascular Treatment Targets in Scleroderma Heart Disease
Current Pharmaceutical Design Extracts and Flavonoids of <i>Passiflora</i> Species as Promising Anti-inflammatory and Antioxidant Substances
Current Pharmaceutical Design